SoloHealth names former Walgreens SVP to board
ATLANTA — SoloHealth, a consumer-driven healthcare technology company, on Wednesday said Stanley Blaylock, former Walgreens SVP and former president of Walgreens Health Services, will join SoloHealth’s board of directors. The announcement comes as SoloHealth prepares for a nationwide rollout in 2012 of its next-generation, consumer health screening kiosk, the SoloHealth Station.
“We are excited and honored that such a respected figure in the healthcare community has agreed to join the SoloHealth board, especially as we ready ourselves for what promises to be a fast-growing and pivotal next 12 to 18 months for the company,” SoloHealth CEO Bart Foster said. “Stan brings unparalleled finance, entrepreneurial and healthcare knowledge to SoloHealth and will provide invaluable counsel during this exciting time of growth as we roll out our new healthcare solution nationwide.”
Blaylock has more than 20 years of experience in the fields of health care, entrepreneurship and investment banking. He began his career in healthcare investment banking, where he rose to the position of global co-head of healthcare investment banking at Deutsche Bank. In this capacity, he oversaw the execution of 149 financings totaling approximately $45 billion and 54 mergers and acquisitions totaling approximately $24 billion.
Blaylock went on to co-found specialty pharmacy solutions company Medmark, where he served as EVP/CFO and chief administrative officer until his promotion to president and CEO in 2005. When Walgreens acquired Medmark in 2006, Blaylock joined the company, and through a series of quick promotions, became Walgreens SVP and president of Walgreens Health Services. Blaylock is credited with successfully integrating Medmark, driving Walgreens' specialty pharmacy to the No. 3 player in the industry through rapid internal growth and key strategic acquisitions. He was responsible for enhancing more than 7,100 community-based pharmacies and managed approximately 7,000 Walgreens employees with P&L responsibility for approximately $4 billion in revenues.
Blaylock currently serves on the board of directors of NovaSom, a provider of home sleep testing services for obstructive sleep apnea. He is also a member of the board of directors of MTS Medication Technologies, an international provider of adherence packaging systems, designed to improve medication dispensing and administration.
He earned a degree in economics and communication studies from the University of Virginia and received his master’s degree in business administration from Harvard Business School. He is also a 2009 fellow of the CEO Perspective Program from Northwestern’s Kellogg School of Management and Corporate Leadership Center.